Our resource hub to discover reports, policy papers and other forms of informative content
…plans. A growing number of European regulatory authorities have been using novel managed entry agreements (MEA) and innovative access agreements (IAA) to accelerate approval times and improve availability to patients….
A growing number of payers in many countries are looking to managed entry agreements (MEAs) and other innovative access arrangements (IAAs) to allow rapid access to medicines that address significant…
…the onset, they worked toward agreements with nations and competitors to increase manufacturing capacity and minimize pharmaceutical supply chain disruption. IMC members demonstrated the industry’s value to the world, as…
…describes innovative agreements being used in jurisdictions outside Canada. We prepared it to guide discussions with the pCPA Governing Council on the merits of jointly developing an innovative agreements framework….
Reimagining Canada’s Approval and Reimbursement System for Innovative Medicines February 2022…
IMC appears before the CIIT to support its study of Canada’s trade agreements and trade and investment policies regarding how they may help or hinder the production and distribution of…
Informative content to keep you up to date on the most pressing issues facing our industry.
